Analyzing Cost of Revenue: Pfizer Inc. and Pharming Group N.V.

Analyzing Cost of Revenue: Pfizer Inc. vs. Pharming Group N.V.

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. Over the past decade, Pfizer Inc. and Pharming Group N.V. have showcased contrasting financial trajectories. Pfizer, a global giant, saw its cost of revenue surge by approximately 250% from 2014 to 2022, peaking in 2022. This reflects its expansive operations and significant market presence. In contrast, Pharming Group N.V., a smaller player, experienced a more modest increase of around 500% in the same period, highlighting its growth phase and strategic investments. Notably, 2021 marked a pivotal year for Pfizer, with costs nearly tripling, likely due to pandemic-related activities. Meanwhile, Pharming's costs remained relatively stable, indicating a steady operational scale. This analysis underscores the diverse strategies and market dynamics influencing these pharmaceutical entities.